@article{9d6411bd5cb7422998d1b03eb9b7856e,
title = "Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020",
author = "Tenforde, \{Mark W.\} and Kim, \{Sara S.\} and Lindsell, \{Christopher J.\} and Rose, \{Erica Billig\} and Shapiro, \{Nathan I.\} and \{Clark Files\}, D. and Gibbs, \{Kevin W.\} and Erickson, \{Heidi L.\} and Steingrub, \{Jay S.\} and Smithline, \{Howard A.\} and Gong, \{Michelle N.\} and Aboodi, \{Michael S.\} and Exline, \{Matthew C.\} and Henning, \{Daniel J.\} and Wilson, \{Jennifer G.\} and Akram Khan and Nida Qadir and Brown, \{Samuel M.\} and Peltan, \{Ithan D.\} and Rice, \{Todd W.\} and Hager, \{David N.\} and Ginde, \{Adit A.\} and Stubblefield, \{William B.\} and Patel, \{Manish M.\} and Self, \{Wesley H.\} and Feldstein, \{Leora R.\}",
note = "Funding Information: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Christopher J. Lindsell reports grants from National Institutes of Health and Department of Defense, and contracts with the Marcus Foundation, CDC, Endpoint Health, Entegrion, bioMerieux, and Bioscape Digital, outside the submitted work. Daniel J. Henning reports personal fees from CytoVale and grants from Baxter, outside the submitted work. Akram Khan reports grants from United Therapeutics, Actelion Pharmaceuticals, Regeneron, and Reata Pharmaceuticals, outside the submitted work. Samuel M. Brown reports grants from National Institutes of Health, Department of Defense, Intermountain Research and Medical Foundation, and Janssen, consulting fees paid to his employer from Faron and Sedana, and royalties from Oxford University Press, outside the submitted work. Ithan D. Peltan reports grants from National Institutes of Health, Asahi Kasei Pharma, Immunexpress Inc., Janssen Pharmaceuticals, and Regeneron, outside the submitted work. Todd W. Rice reports personal fees from Cumberland Pharmaceuticals, Inc., Cytovale, Inc., and Avisa, LLC, outside the submitted work. No other potential conflicts of interest were disclosed.",
year = "2020",
month = jul,
doi = "10.15585/MMWR.MM6930E1",
language = "English",
volume = "69",
pages = "993--998",
journal = "Morbidity and Mortality Weekly Report",
issn = "0149-2195",
number = "30",
}